



**REPORT OF VOTING RESULTS**  
**SECTION 11.3 OF NATIONAL INSTRUMENT 51-102**

In accordance with section 11.3 of National Instrument 51-102 *Continuous Disclosure Obligations*, the following is a summary of the results of the matters voted on at the annual and special meetings of the holders of the common shares (the “**Shareholders**”) of MediPharm Labs Corp. (“**MediPharm Labs**”) held on June 30, 2022 (the “**Meeting**”).

There were 293 shareholders represented virtually or by proxy at the Meeting holding 56,374,684 common shares, representing 20.564% of MediPharm Labs total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by a ballot vote.

**1. Election of Directors**

Each of the nominees for election as directors were elected as directors of MediPharm Labs for the ensuing year or until their successors are elected or appointed. Voting results for the election of the individual directors are as set out below:

<b>Nominee</b>	<b>Votes For</b>	<b>Votes Withheld</b>
	<b>#</b>	<b>#</b>
Chris Halyk	36,883,329	3,554,621
Shelley Martin	36,960,397	3,457,553
Miriam McDonald	33,318,261	7,119,689
David Pidduck	37,912,649	2,525,301
Chris Taves	29,147,199	11,290,751



## 2. Appointment of Auditor

KPMG LLP, Chartered Professional Accountants, was appointed auditor of MediPharm Labs until the next annual meeting of the holders of the Shareholders at remuneration to be fixed by the directors. Voting results are as set out below:

<b>Votes For</b>	<b>Votes Withheld</b>
<b>#</b>	<b>#</b>
52,284,746	4,069,938

## 3. Amendment to Equity Incentive Plan

An amendment was approved to the Company's rolling long-term omnibus equity incentive plan to increase the plan limit from 10% to 15%. Voting results are as set out below:

<b>Votes For</b>	<b>Votes Against</b>
<b>#</b>	<b>#</b>
30,897,488	9,540,462